The clinic pathological features of the patients, such as overall survival (OS), lymph node metastasis (LNM) and high tumor stage (II/III/IV) (HTS), are also highly correlated with the level of GAS5 expression in these cancers (Gee et al., 2011; Cao et al., 2014; Sun et al., 2014; Tu et al., 2014; Yin et al., 2014; Gao et al., 2015; Shi et al., 2015; Chang et al., 2016; Hu et al., 2016; Li J. et al., 2016; Wu et al., 2016; Droop et al., 2017; Li et al., 2017; Zhang et al., 2017). The gene discussed is GAS5; the disease is cancer.